- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Cancer
Small charity eases struggles of breast cancer patients
October 6, 2012
Dan HumanWith volunteer leader Nancy Shepard at the helm, IWIN Foundation has distributed $875,000 in grants to breast cancer patients.
Recipients have ranged in age from 18 to 90.
MoreSledge's exit will keep IU program mostly intact
October 1, 2012
J.K. WallThe departure of Dr. George Sledge likely will sap the breast cancer research program at the Indiana University Melvin and
Bren Simon Cancer Center of about $500,000 in annual funding. But the program Sledge built over the past three decades mostly
will remain intact.
MoreLilly wins appeal upholding patent for Alimta cancer drug
August 24, 2012
Bloomberg NewsEli Lilly and Co. won a U.S. appeals court ruling that upholds the validity of a patent for the lung-cancer drug Alimta and
blocks generic competition through 2017. Alimta generated $2.5 billion in sales last year.
MoreIndiana Blood Center tapping new vein of revenue
July 28, 2012
Mason KingGroup sees role in cellular therapy as growth area with profit margins higher than core business.
MoreLilly cancer treatment fails trial in stomach cancer
July 5, 2012
IBJ Staff and Bloomberg NewsErbitux, a cancer treatment made by Indianapolis-based Eli Lilly and Co.'s Imclone unit, failed to help patients with
advanced stomach tumors in a late-stage clinical trial.
MoreCancer tools help Roche with Alzheimer's drug
May 13, 2012
Bloomberg NewsTreatments for central nervous system diseases have a huge potential payoff, analysts say. A hint of whether the gamble may
pay off is due in the second half of this year, as Eli Lilly and Co. and Pfizer Inc. announce results for Alzheimer’s drugs
that attack the same protein as Roche’s experimental drug.
MoreWellPoint enrolls IBM supercomputer at IU medical school
April 21, 2012
J.K. WallIBM’s supercomputer Watson is already a “Jeopardy!” champion. Now, three doctors in Indianapolis are trying
to teach it how to treat cancer.
MoreKomen grant recipients cope with controversy they didn't create
April 7, 2012
Kathleen McLaughlinLocal health care providers won’t find an easy replacement for the grant money supplied by Susan G. Komen for the Cure.
That money could be in jeopardy, as grass-roots Komen supporters appear to be sitting out of this year’s Race for the
Cure in response to a national controversy over grants to Planned Parenthood.
MoreEndocyte pulls trigger on European drug submission
March 13, 2012
J.K. WallEndocyte Inc. will submit its ovarian cancer drug EC145 for European market approval in the third quarter of this year after
the European Commission granted it orphan drug status.
MoreEndocyte stays course despite being battered by investors
December 31, 2011
J.K. WallAfter spending most of 2011 as a Wall Street darling, the year ended ugly for Endocyte Inc. But CEO Ron Ellis thinks the West
Lafayette-based drug developer is in better position than ever.
MoreNFP of NOTE: Little Red Door Cancer Agency
December 31, 2011
IBJ StaffLittle Red Door Cancer Agency strives to make the most of life and the least of cancer.
MoreQ&A
December 27, 2011
J.K. WallDr. Bryan Schneider, a professor at the Indiana University School of Medicine, led a team of researchers in identifying genetic variations that dispose some breast cancer patients to neuropathy when they are receiving chemotherapy with the drug Taxol. Schneider’s research was named one of the biggest advances in cancer research this year by the American Society of Clinical Oncology. The society’s foundation also gave Schneider a three-year, $450,000 grant to further the research.
Q&A
December 5, 2011
J.K. WallCarmel resident David Wasilewski has launched WhatNext, a website that uses algorithms to make it easier
for cancer patients to connect with others in similar circumstances. Wasilewski, 39, spent eight years as chief operating
officer of the Spanx line of body shapers and did health care consulting before that. In addition to helping patients, he
thinks WhatNext can become a way for health care organizations share their expertise with patients in need.
MoreLilly's Alimta get favorable opinion for new use in Europe
September 26, 2011
J.K. WallIf approved for continuation maintenance, Eli Lilly and Co.'s Alimta could be used for longer stretches in lung cancer patients,
generating more revenue.
MoreDebate rages over whether Lilly's Byetta lifts cancer risk
September 16, 2011
Bloomberg NewsA German researcher disputed the validity of a study that found Byetta and another diabetes drug increase cancer risk.
MoreIU Cancer Center recruits top researcher
September 15, 2011
Scott OlsonDr. Murray Korc, an internationally known pancreatic cancer researcher, comes to the cancer center as the first Myles Brand
Professor of Cancer Research. The position is funded through a Lilly Endowment grant.
MoreIU Health strikes deal with Central Indiana Cancer Centers
June 17, 2011
J.K. WallCentral Indiana Cancer Centers sold its five facilities to IU Health and transferred its 150 employees to the Indianapolis-based
hospital system. The 16 physicians in the practice will remain independent, but they have signed a service agreement with
IU Health that pulls the two entities into a tight embrace.
MoreTrade agency to probe Lilly's infringement claim
March 17, 2011
Bloomberg NewsEli Lilly and Co.’s patent-infringement claim over Hospira Inc.’s generic version of the cancer treatment Gemzar will be investigated
by a U.S. trade agency with the power to block imports of the copycat drug.
MoreRepeated price cuts take glow off Endocyte IPO
February 12, 2011
Greg AndrewsNew investors got in for $6 a share—which is less than the average price paid by prior investors, a regulatory filing
reveals.
MoreHead of Lilly's oncology unit resigning
January 25, 2011
John H. Johnson has been hired as CEO by East Brunswick, N.J.-based biotechnology company Savient Pharmaceuticals Inc.
MoreLilly suspends late-stage trial for melanoma drug
December 13, 2010
Bloomberg NewsEli Lilly and Co. suspended a late-stage clinical trial of a medicine for skin-cancer patients after 12 patients in the study
died.
MoreGroup says billboard companies rejected anti-Lilly ad
November 3, 2010
Scott OlsonSan Francisco-based Breast Cancer Action wanted its message, "Eli Lilly is making us sick. Tell them to stop," posted on local
billboards. But numerous sign companies refused, the group said.
MoreCancer researcher battling Semafore in court
May 29, 2010
Chris O'MalleyFormer collaborator alleges firm breached its agreement with him and refused to pay royalty income.
MorePositron has billion-dollar hopes for medical-imaging scanner
May 29, 2010
J.K. WallA maker of medical imaging equipment that recently moved its headquarters to Fishers has grand plans to reach $1 billion in
sales and build a multimillion-dollar cyclotron facility in five years. But history shows Positron Corp. has been far better
at losing money than making it.
MoreWellPoint pledges two-day hospital stays after mastectomy
May 26, 2010
J.K. WallIn the company's latest response to withering criticism of its breast-cancer policies, WellPoint Inc. said it will pay
for any breast cancer patient to stay two days in a hospital after surgery.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
liek the rest of America
These quaint,obsessed musings by the stalkers are certainly entertaining, but I'm trying to figure out what, if anything, all the yelping below has to do with Zak Brown.
It's evident that Moffett was pushing the right buttons and corporate America is now trying to squash him. He just wanted to withdraw the free pilot services provided to the company by the pilots to try and put some pressure on a company that has not been interested in negotiating a contract in over 5 years. The company does not provide a contract because not having one has saved them a bundle of money. Shame on any Republic pilots not standing behind their union leader just because things are getting tough, can you not see such strategic moves by the company as putting the last union president in a corporate position and into THEIR pocket. Do you really believe the last union president is so appalled at the attempts by Moffett, do you not remember his oppositions to the company? We stood behind him. It has been proven over and over again for thousands of years without fail, a man cannot serve two masters. Anyone that believes people vote contrary to their paycheck and livelihood deserve to be taken advantage of, the recent statements by the former union president are laughable as he denounces the current union president from his new corporate position. Have you ever seen a drafted sports player score points for his previous team, it cannot be done, he is not on the pilots side anymore, he gets his money a different way now than you and I do, and he should not be allowed to remain on the seniority list. A drafted player brings strength, credibility, tactical knowledge, and a strategic advantage to his NEW team, he would not be drafted or paid were it otherwise. We are all forced to choose only one side to play for and support, not doing so has many references in life such as insider trading and shaving points, all illegal for good reason. This basic fact is why corporate moguls, scientist, and engineers all sign non-discloser agreements and non-compete clauses, as protection in case they are lured into switching sides as our former union president has done. No NFL coach ever drafted a player so that both teams could benefit and better understand each other, they are recruited to win the game against that former team, period. Likewise the company does not recruit the former union president by accident or mutual understanding, its strategy. Don't confuse playing the game with good sportsman-like conduct in support of common business and prosperity goals, with the requirement to only play for one side. Good men we all love and favor fall subject to this manipulation, often without their knowledge, and it is not a betrayal of their friendship to oppose them when they switch sides. If we did not love and trust them, they would not have been chosen and lured to the other side in the first place. The deception by the drafted player is not made at a conscious level, it's just human nature and it's all about money and power which corrupts our ability to be objective and loyal to two masters. This is why our court system created the defense attorney, and why our military created counter intelligence. Its strategy and its propaganda, and it works, and that's why the "powers to be" manipulate the chess pieces by sometimes changing their colors. Some players know they are being manipulated when their color is changed, but it brings them more money and power so they do not care. The rest have good intentions but do not even realize they are being manipulated. This tactic is also known by another name, Divide and Conquer. In battle sending an imperfect message with an imperfect team is obviously not ideal, but it's still being sent by YOUR team, your union leader, a leader that has common goals and common rewards with you, they are the best, because we have elected them to do a job for us. If you are not backing Moffett but believing the spin by those that have recently switched sides, you are taking food out of your own mouth. Showing unity and backing an imperfect situation still results in taking just as much ground, it's about unity and bargaining power. It's not necessary to wait around for that perfect attack because it will never come, the company will spin and attempt to destroy anyone that gets in their way. Ultimately it's not about any specific attack anyway, ASAP or whatever it makes no difference, it is and always has been only about power. If this company cared about safety it would not build pairings with 8 hour overnights, come on, are you that naive? Besides, do you really think Hoffa cares, no, he got a call from corporate America and was squeezed into denouncing Moffett. If he didn't they would spin the safety card against him and the Teamsters National with implication for truckers, future contracts, insurance rates etc...saying something like the Teamsters use safety as a bargaining chip, blah blah blah... Do you really think any pilot is going to do something unsafe for the contract, absolutely not, the only ones threatening safety here is the company with reduced rest, fatigue, and poverty. Do you not find it odd that Hoffa and the Teamsters are opposing a Teamster president publicly? Would the Teamsters National not normally support and work with one of their own? Why did they not sit down and help him strategize, correct any mistakes, and charge ahead? Would the Teamsters National not normally support and leverage a contract for all those pilots that have been paying Teamster dues, isn't that why we have all been paying Teamster dues in the first place? I sure haven't been paying dues so that the Teamsters National could come along and write this kind of an article undercutting our union leader and our unity. Whose side is the Teamsters National really on, it's obviously not the Republic pilots side.
No matter what Moffatt does the company is going to spin it like he is the terrorist and brainwash people like you into believing it, wake up, back your players that are trying to change things for you and your livelihood. Where has Hoffa been for the last 6 years, except collecting our dues. Seriously, do you really think an FO going for upgrade, signed off by a checkairman ready for the upgrade, who then fails, is not even capable of returning as a First Officer.
whoa!